The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
Erika P. Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer; Puma Biotechnology
 
Muralidhar Beeram
Honoraria - Genentech (Inst); Johnson & Johnson (Inst)
Consulting or Advisory Role - Bayer (I); Merck (I); Novartis (I); Seagen (I)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Research Funding - Agios (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Phoenix Molecular Designs (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Genentech; Merck
 
Diana L. Hanna
Consulting or Advisory Role - Boehringer Ingelheim
 
Anthony B. El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Keun Wook Lee
Honoraria - Bristol-Myers Squibb; Genexine; Lilly
Consulting or Advisory Role - Bayer; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Sun Young Rha
Consulting or Advisory Role - Abbvie; Amgen; Daiichi Sankyo; Eisai; Ipsen; MSD Oncology; Novartis
Speakers' Bureau - Ipsen; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Cellid; Eisai; Immunome; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Jorge M Chaves
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Ipsen
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ACRUS (Inst); Boryung (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Laekna Therapeutics (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Zymeworks (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; Lilly; Novartis
 
Rachel Anne Goodwin
Honoraria - Celgene; Eisai; Ipsen; Merck; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Celgene; Eisai; Ipsen; Merck; Novartis; Pfizer; SERVIER
Speakers' Bureau - Eisai; Ipsen
Research Funding - Ipsen
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Lilly; Merck; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Todd Gray
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
Other Relationship - Zymeworks
 
Joseph Woolery
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Zymeworks (Inst)
Research Funding - Bristol-Myers Squibb; Zymeworks